Algernon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Algernon Pharmaceuticals's earnings have been declining at an average annual rate of -3.2%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.
Key information
-3.2%
Earnings growth rate
26.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | -132.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 May 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Algernon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 May 24 | 0 | -3 | 2 | 1 |
| 29 Feb 24 | 0 | -5 | 2 | 1 |
| 30 Nov 23 | 0 | -5 | 3 | 1 |
| 31 Aug 23 | 0 | -7 | 4 | 1 |
| 31 May 23 | 0 | -6 | 5 | 2 |
| 28 Feb 23 | 0 | -6 | 5 | 1 |
| 30 Nov 22 | 0 | -7 | 4 | 2 |
| 31 Aug 22 | 0 | -6 | 3 | 2 |
| 31 May 22 | 0 | -4 | 3 | 1 |
| 28 Feb 22 | 0 | -5 | 3 | 2 |
| 30 Nov 21 | 0 | -6 | 3 | 3 |
| 31 Aug 21 | 0 | -8 | 3 | 5 |
| 31 May 21 | 0 | -10 | 4 | 6 |
| 28 Feb 21 | 0 | -13 | 7 | 6 |
| 30 Nov 20 | 0 | -12 | 6 | 5 |
| 31 Aug 20 | 0 | -9 | 6 | 3 |
| 31 May 20 | 0 | -6 | 4 | 2 |
| 29 Feb 20 | 0 | -2 | 1 | 0 |
| 30 Nov 19 | 0 | -2 | 1 | 0 |
| 31 Aug 19 | 0 | -2 | 1 | 1 |
| 31 May 19 | 0 | -2 | 1 | 1 |
| 28 Feb 19 | 0 | -2 | 1 | 0 |
| 30 Nov 18 | 0 | -1 | 1 | 0 |
| 31 Aug 18 | 0 | -1 | 1 | 0 |
| 31 May 18 | 0 | -1 | 1 | 0 |
| 28 Feb 18 | 0 | -1 | 1 | 0 |
| 30 Nov 17 | 0 | -2 | 1 | 0 |
| 31 Aug 17 | 0 | -2 | 1 | 0 |
| 31 May 17 | 0 | -2 | 1 | 0 |
| 28 Feb 17 | 0 | -2 | 1 | 0 |
| 30 Nov 16 | 0 | -3 | 3 | 0 |
| 31 Aug 16 | 0 | -7 | 3 | 0 |
| 31 May 16 | 0 | -7 | 3 | 0 |
Quality Earnings: AGN is currently unprofitable.
Growing Profit Margin: AGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGN is unprofitable, and losses have increased over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: AGN has a negative Return on Equity (-132.91%), as it is currently unprofitable.